How Johnson & Johnson Makes its Money: Revenue Breakdown

How Does Johnson & Johnson Make its Money?

Johnson & Johnson (NYSE: JNJ) is one of the world’s largest healthcare companies, generating $88.8 billion in total revenue for fiscal year 2024 across two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). J&J is the rare healthcare company with genuine scale in both drugs and devices — a combination that provides revenue diversification across different growth cycles, regulatory environments, and reimbursement dynamics.

The company underwent its most significant strategic transformation in decades in August 2023, when it spun off Kenvue (NYSE: KVUE) — its consumer health business comprising brands like Tylenol, Band-Aid, Listerine, Neutrogena, and Aveeno. The spinoff created a separate publicly traded consumer products company and left J&J as a focused, higher-margin pharmaceutical and medical device business. The strategic logic: consumer brands grow at 2–4% annually and trade at consumer staples multiples; patented pharmaceuticals grow at 5–10% and trade at premium healthcare multiples. Separating the two unlocks valuation for both.

J&J has delivered 62 consecutive years of dividend increases — one of only a handful of companies globally with this record — making it a Dividend King and a core holding for income-focused institutional and retail investors.

Key Takeaways

• J&J generated $88.8B in FY2024 revenue, up 4.2%, with $14.1B in net income and a 68% gross margin — a healthcare company with pharmaceutical-level profitability
• Innovative Medicine (64% of revenue) is the growth engine: Darzalex ($10.8B, multiple myeloma) and Tremfya (psoriasis) are the fastest-growing flagship drugs, offsetting the Stelara biosimilar cliff beginning in 2025
• Stelara ($10.4B) — J&J’s largest single drug — faces biosimilar competition from 2025 onward; managing this erosion while growing the replacement portfolio is the most critical near-term execution challenge
• Carvykti (CAR-T cell therapy for multiple myeloma) is growing rapidly and could become a multi-billion dollar franchise as manufacturing capacity expands and it moves into earlier lines of therapy
• MedTech (36% of revenue) is growing steadily, led by electrophysiology (Biosense Webster, double-digit growth) and a global robotic surgery push through the Ottava platform — J&J’s answer to Intuitive Surgical
• The Kenvue spinoff (August 2023) transformed J&J into a focused pharmaceutical and device company — stripping out slow-growing consumer brands to sharpen the growth and margin profile
• Talc litigation — thousands of claims over talc-based baby powder causing ovarian cancer and mesothelioma — remains the most significant legal overhang; J&J has pursued settlement through its subsidiary’s bankruptcy restructuring
• R&D budget of $14.9B (one of the largest in healthcare) funds ~50 late-stage clinical programmes, providing a deep pipeline to replace products facing patent expiry
• J&J has raised its dividend for 62 consecutive years — a record shared by fewer than 10 companies globally

Johnson & Johnson (JNJ) Business Model

J&J operates a dual-platform healthcare model across pharmaceuticals and medical devices, with fundamentally different economics in each segment:

Innovative Medicine: The Patent-Protected Pharmaceutical Model

J&J’s pharmaceutical business earns money by developing, patenting, and commercialising drugs that treat serious diseases. The economics of this model are extraordinary when it works and brutal when it doesn’t:

How pharma revenue is generated:

• J&J researches and develops drug compounds internally through its Janssen pharmaceutical division, spending years and billions of dollars on basic research, clinical trials, and FDA/EMA regulatory approval
• Upon approval, J&J markets the drug under patent protection — typically 10–15 years of exclusivity from the original patent filing date, though effective commercial exclusivity is often 7–12 years from launch
• During exclusivity, J&J sets the drug price with significant leverage — there is no generic competitor, and for life-altering treatments (cancer, autoimmune disease), payors have limited ability to refuse coverage
• Revenue is recognised upon delivery to wholesalers, adjusted for rebates and discounts negotiated with pharmacy benefit managers (PBMs) and government payors (Medicaid, Medicare Part D)
• When patent exclusivity expires, generic or biosimilar competitors enter and prices collapse — often 80–95% within 2–3 years for small molecules (generics), and more gradually for biologics (biosimilars, due to their manufacturing complexity)

J&J’s therapeutic focus areas:

Immunology — J&J has built one of the most valuable immunology franchises in the world. Stelara (ustekinumab) targets IL-12/23 pathways to treat psoriasis, Crohn’s disease, and ulcerative colitis. At peak, Stelara was generating over $10B annually — one of the best-selling drugs in history. Tremfya (guselkumab) targets IL-23 specifically and is now the primary immunology growth driver as Stelara faces biosimilar competition.

Oncology — Darzalex (daratumumab), developed for multiple myeloma (a blood cancer), has become one of the world’s best-selling oncology drugs at $10.8B. Its success reflects a pattern J&J has mastered: launch a drug in a late-stage treatment setting, generate survival data, then expand approval into earlier lines of therapy — broadening the treatable patient population at each step. Carvykti (ciltacabtagene autoleucel) is J&J’s CAR-T cell therapy, a personalised treatment that engineers a patient’s own T-cells to attack myeloma cells. It is growing rapidly but constrained by manufacturing complexity.

Neuroscience — Spravato (esketamine nasal spray) is the first genuinely new mechanism for treatment-resistant depression in decades, delivered in a clinical setting due to dissociation risk. It is a growing but operationally complex commercial product. J&J’s neuroscience pipeline also targets Alzheimer’s disease prevention and treatment.

Cardiovascular/Metabolic — Xarelto (rivaroxaban) is a blood thinner (anticoagulant) co-promoted with Bayer, generating declining revenue as it loses exclusivity. The replacement portfolio focuses on pulmonary hypertension (Johnson & Johnson acquired Actelion in 2017 for $30B for this purpose) and other cardiovascular indications.

Infectious Disease — J&J developed a COVID-19 vaccine (Johnson & Johnson vaccine, single-dose, adenovirus vector) that generated significant revenue in 2021–2022 before demand collapsed. The ID pipeline now focuses on HIV, tuberculosis, and respiratory viruses.

MedTech: The Procedure-Volume and Hospital Capital Equipment Model

J&J’s MedTech segment earns money differently from pharmaceuticals:

• Capital equipment model: High-value surgical systems (like the Ottava robotic surgery platform) are sold or leased to hospitals; Ottava will follow Intuitive Surgical’s playbook — place the robot at a price, then earn recurring revenue from single-use instruments and accessories used in each procedure
• Implant/disposable model: Orthopedic implants (hips, knees, spines) are sold per-implant, driven by procedure volume. Revenue grows when patient volumes increase, when J&J wins market share, and when hospitals upgrade to J&J’s premium product lines
• Consumable/lens model: Acuvue contact lenses are a classic consumable subscription — patients replace lenses daily, biweekly, or monthly, generating recurring per-unit revenue
• Electrophysiology model: Biosense Webster makes catheters and mapping systems for treating heart rhythm disorders (atrial fibrillation). Like surgical robots, the system creates lock-in: hospitals that map with Carto (J&J’s mapping platform) buy Biosense Webster catheters to use with it

MedTech revenue is more predictable than pharmaceutical revenue — it doesn’t face the patent-cliff dynamic — but grows more slowly and is more sensitive to hospital capital expenditure cycles and procedure volume trends.

The Kenvue Spinoff: Why J&J Shed Its Consumer Brands

Understanding why J&J spun off Kenvue is essential to understanding the J&J that investors own today.

What Kenvue contained: Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno, Rogaine, Nicorette, and other consumer health brands — businesses generating roughly $15B in annual revenue with 3–5% growth and consumer staples-level margins.

Why J&J separated it: Consumer health brands are fundamentally different from pharmaceuticals and medical devices:

• They grow at 2–4% annually (in line with GDP), not 5–15% (pharma with pipeline launches)
• They trade at 20–25x earnings (consumer staples multiples), not 25–35x earnings (healthcare/pharma multiples)
• They require different management capabilities (brand marketing, retail distribution) vs. pharmaceutical R&D and hospital sales
• They diluted J&J’s margin profile — consumer brands carry lower gross margins than patented drugs

By spinning out Kenvue, J&J shed slow-growing, lower-multiple businesses and retained only its highest-margin, highest-growth assets. The remaining J&J is a cleaner, higher-multiple pharmaceutical and device company — even if the absolute revenue base is smaller.

The unintended benefit: Kenvue inherited a portion of the talc litigation liability (related to consumer talc products), providing J&J with some legal exposure reduction as part of the separation structure.

Johnson & Johnson Competitors

J&J’s competitive landscape differs significantly by segment:

Innovative Medicine competitors:

• AbbVie — the most directly comparable peer. AbbVie’s Humira was the world’s best-selling drug for over a decade; like J&J with Stelara, AbbVie faced a biosimilar cliff for Humira (which began in 2023) and is navigating it with Skyrizi and Rinvoq as growth drivers. AbbVie and J&J compete directly in immunology (Skyrizi vs. Tremfya in psoriasis and Crohn’s disease) and oncology
• Pfizer — competes in oncology, vaccines, and rare disease; Pfizer’s commercial scale and pipeline breadth make it a broad competitor across multiple J&J therapeutic areas
• Eli Lilly — less overlap with J&J today, but Lilly’s oncology and neuroscience pipeline (Donanemab for Alzheimer’s) creates long-term competitive tension in J&J’s neuroscience ambitions
• Merck (Keytruda) and Bristol-Myers Squibb (Opdivo/Eliquis) compete in oncology and cardiovascular respectively
• Novartis, Roche, and AstraZeneca are the primary European pharmaceutical competitors across J&J’s therapeutic areas

MedTech competitors:

• Intuitive Surgical — the dominant competitor in robotic surgery. Intuitive’s da Vinci system has ~80% market share in soft tissue robotic surgery. J&J’s Ottava is specifically designed to compete with da Vinci — a high-stakes, multi-year battle for the hospital robotics market
• Medtronic — the largest pure-play medical device company; competes across orthopedics, spine, cardiovascular, and minimally invasive surgery
• Stryker — orthopedic and surgical equipment competitor; strong in hips/knees where J&J’s DePuy Synthes competes
• Abbott — competes in electrophysiology (EP mapping and ablation catheters) against J&J’s Biosense Webster
• Alcon and CooperVision — contact lens competitors against Acuvue in the vision care market

Revenue Breakdown

Financial data sourced from Johnson & Johnson SEC Filings.

Innovative Medicine — 64% of Revenue ($57.1B)

Key drug revenue (FY2024):

Darzalex — the growth anchor: At $10.8B with 19% growth, Darzalex is now one of the top-selling drugs globally. It was initially approved for relapsed/refractory multiple myeloma (patients who had already tried multiple prior treatments). J&J has since expanded Darzalex’s approval into newly diagnosed myeloma — a dramatically larger patient population. The drug is now used as a frontline treatment in combination with other myeloma drugs, and further expansion into smoldering myeloma (pre-disease) is in clinical trials. The Darzalex story is J&J’s pharmaceutical strategy in miniature: win initial approval, expand indications aggressively, extend the revenue cycle.

Stelara — the managed decline: Stelara generated $10.4B in FY2024, making it J&J’s second-largest drug. Biosimilar competition in the US and Europe began in 2025. Unlike small-molecule generics (which cause rapid 80–95% price erosion), biologics biosimilars penetrate more slowly — 20–40% of prescription share in the first 2–3 years. J&J has been managing this through long-term contracts with payors, patient support programmes, and price negotiations. Stelara revenue will decline materially from 2025 onward — the key question is how fast, and whether Tremfya, Darzalex growth, and new launches fully offset it.

Tremfya — the immunology successor: Tremfya targets IL-23 specifically (vs. Stelara’s IL-12/23 dual target) and has demonstrated superior efficacy in some head-to-head trials. Growing 21% to $4.1B, it is J&J’s designated successor to Stelara in psoriasis and is now approved for Crohn’s disease and psoriatic arthritis — expanding its market significantly. Tremfya’s long-term potential is $10B+ if it can capture Stelara’s patient base plus grow the broader market.

Carvykti — the high-risk, high-reward bet: CAR-T cell therapy (chimeric antigen receptor T-cell therapy) is among the most transformative cancer treatments developed in the last decade. Carvykti achieved $1.1B in its first full year of broad commercial availability, with 82% growth. Manufacturing capacity has been the primary constraint — each dose of Carvykti is manufactured individually from a specific patient’s T-cells, a complex, weeks-long process. J&J and its partner Legend Biotech are expanding manufacturing. Moving Carvykti into earlier myeloma treatment lines (before patients have exhausted other options) would multiply the treatable population.

MedTech — 36% of Revenue ($31.2B)

Key MedTech sub-segments (FY2024):

Electrophysiology — the standout: Biosense Webster is growing double digits, driven by surging atrial fibrillation (AF) ablation procedure volumes. AF is one of the most common cardiac arrhythmias; catheter ablation (destroying the tissue causing abnormal electrical signals) is increasingly preferred over lifelong medication. J&J’s Carto 3 mapping system and a broad portfolio of diagnostic and ablation catheters position it as a leader in a market growing 10–15% annually as procedure volumes expand.

Orthopaedics — the slow grower: DePuy Synthes makes hip and knee replacement implants, spine products, and trauma fixation devices. Orthopaedic revenues grow at 2–4%, driven by aging populations, increased procedure volume, and modest pricing. This is a stable business but not a growth engine; J&J has been investing in robotic-assisted orthopaedic surgery (VELYS robotic platform) to defend and grow share.

Ottava — the long-term MedTech catalyst: Ottava is J&J’s robotic surgery platform, designed to compete directly with Intuitive Surgical’s da Vinci in soft tissue surgery. Intuitive Surgical is the dominant incumbent with ~80% market share and a deeply entrenched hospital customer base. J&J is pursuing a differentiated approach: a modular design that allows the robot to be configured for different surgical specialties. Ottava received its first regulatory approval and early commercial placements are underway. If Ottava achieves meaningful adoption, it transforms MedTech’s growth trajectory — but competing against Intuitive’s installed base and surgeon training ecosystem is a multi-year, high-investment battle. See How Intuitive Surgical Makes its Money for the competitive context.

Revenue Trend (3-Year)

FY2022 includes the Consumer Health segment (subsequently spun into Kenvue); not directly comparable to FY2023–2024.

The apparent “revenue decline” from FY2022 to FY2023 reflects the Kenvue spinoff removing ~$15B in consumer health revenue — not underlying business deterioration. On a comparable (ex-Consumer) basis, J&J has grown consistently.

Johnson & Johnson (JNJ) Income Statement

Financial data sourced from Johnson & Johnson 2024 Annual Report and SEC 10-K.

Johnson & Johnson (JNJ) Key Financial Metrics

• Gross Margin: 68.0% — Reflects the pharmaceutical-dominant revenue mix. Patented drugs carry 80–90% gross margins; medical devices carry 60–70%. As Innovative Medicine grows faster than MedTech, the blended gross margin expands over time. The 68% figure is consistent with large-cap pharmaceutical peers and significantly above pure medical device companies

• Operating Margin: 26.4% — Improved from 22.2% in FY2023, reflecting post-Kenvue operating leverage and reduced restructuring charges. J&J’s operating margin is moderated by its $14.9B R&D investment (16.8% of revenue) — one of the largest R&D budgets in healthcare. Without that investment, margins would be substantially higher, but the pipeline is what sustains the business long-term

• R&D Spending: $14.9B (16.8% of revenue) — J&J’s R&D budget supports approximately 50 late-stage clinical programmes. Key priorities: Tremfya label expansions, Carvykti manufacturing/clinical expansion, Ottava robotic surgery, pulmonary hypertension portfolio, and multiple Phase 3 oncology and neuroscience studies. Each successful programme adds years of future revenue; each failure is a write-off

• Dividend: 62 consecutive years of increases — J&J’s dividend yield of approximately 3.1% is meaningful for a large-cap healthcare company. The payout ratio remains manageable relative to free cash flow ($18B+), providing ample room for continued dividend growth. Dividend Kings (50+ consecutive years of increases) are extremely rare — J&J shares this distinction with fewer than 10 companies globally

• Free Cash Flow: ~$18B — Comfortably covers the dividend ($5B+), bolt-on acquisitions, and share buybacks. J&J’s balance sheet (AAA credit rating from S&P, one of only two US companies with a AAA rating alongside Microsoft) provides capacity for transformative M&A when strategic opportunities arise

• Return on Equity — J&J’s ROE has historically run 20–30%, reflecting the capital-efficient nature of the pharmaceutical model (high margins, relatively modest capital requirements compared to capital-intensive industries)

The Talc Litigation: Understanding the Legal Overhang

The talc litigation is the most discussed legal issue in J&J’s investor narrative and requires careful understanding — because the popular framing and the financial reality differ significantly.

What the litigation is about: Tens of thousands of plaintiffs claim that Johnson’s Baby Powder and Shower to Shower talc products (manufactured by J&J and its subsidiaries) contained asbestos that caused ovarian cancer and mesothelioma. J&J disputes that its talc contained asbestos and disputes causation.

The “Texas Two-Step” bankruptcy strategy: J&J created a subsidiary (LTL Management LLC) specifically to hold talc liabilities, then had that subsidiary file for Chapter 11 bankruptcy — a controversial legal manoeuvre called a “divisional merger” or “Texas Two-Step.” The strategy was designed to use the bankruptcy process to achieve a comprehensive, final settlement covering all current and future talc claims. The first two bankruptcy attempts were dismissed by courts as not being filed in good faith. A third attempt was filed in 2024 with a proposed $8B+ settlement fund.

The financial reality: J&J has reserved approximately $6–9B for talc resolution across different settlement scenarios. For a company generating $18B+ in annual free cash flow, even a $10B settlement is painful but manageable — roughly 6–7 months of free cash flow, spread over payment periods. The legal overhang depresses the stock’s multiple (investors assign a valuation discount for unresolved contingent liabilities), but a final settlement would remove this discount and could be a significant positive catalyst for the stock

Status as of 2024–2025: Ongoing litigation and settlement negotiations. The outcome remains uncertain but a negotiated comprehensive settlement — which J&J and plaintiff’s lawyers both have incentives to reach — is the base case for most analysts.

Is Johnson & Johnson Profitable?

Yes. J&J is one of the most consistently profitable companies in the world, reporting $14.1 billion in net income on $88.8 billion in revenue in FY2024 — a 15.9% net margin. The company has been continuously profitable for well over a century and has never cut its dividend.

J&J’s profitability is structural: the pharmaceutical model (patent-protected drugs with 80–90% gross margins) combined with the scale of a near-$90B revenue base creates extraordinary earnings durability. Even during patent cliffs (like the current Stelara challenge), J&J’s diversified portfolio and continuous pipeline output prevent the kind of earnings collapse that smaller, single-product pharmaceutical companies face.

The FY2023 operating margin of 22.2% was depressed by Kenvue spin-related charges and restructuring costs; the recovery to 26.4% in FY2024 reflects the clean post-spinoff operating structure. Management has guided for continued margin expansion as Tremfya, Darzalex, and Carvykti scale and operating leverage materialises.

Johnson & Johnson (JNJ): What to Watch

1. Stelara biosimilar erosion rate — Stelara ($10.4B, J&J’s second-largest drug) faces biosimilar competition beginning in 2025. The erosion rate matters enormously: a slower-than-expected decline (20–25% volume loss in year one) vs. a faster decline (40–50%) has a multi-billion dollar impact on earnings. Watch quarterly Stelara revenue against analyst consensus; the rate of payor formulary switches to biosimilars is the key leading indicator

2. Tremfya’s label expansion progress — Tremfya’s approval in Crohn’s disease (received 2023) opens a market larger than psoriasis alone. Additional label expansions (ulcerative colitis, other inflammatory conditions) would further extend its peak revenue potential. Clinical trial readouts for new Tremfya indications are key watch items through 2025–2027

3. Carvykti manufacturing ramp — At $1.1B with 82% growth, Carvykti’s ceiling is constrained by manufacturing capacity. Each dose is a bespoke, patient-specific biological product with a complex 4–6 week manufacturing process. Expansion of manufacturing slots at J&J and partner Legend Biotech’s facilities is the primary lever for accelerating revenue growth. Watch for capacity announcements and manufacturing site expansions

4. Ottava regulatory clearance and hospital adoption — J&J’s robotic surgery platform is entering commercial launch. Initial clearances and the first hospital placements will determine whether Ottava can credibly challenge Intuitive Surgical’s da Vinci dominance. Surgeon training volumes, procedure counts, and repeat instrument sales are the key metrics once commercial placements begin

5. Talc litigation resolution — A comprehensive settlement covering all current and future talc claims would remove the most significant legal overhang on the stock. The proposed $8B+ settlement fund requires sufficient plaintiff acceptance rates to be binding. Progress in the bankruptcy proceedings, plaintiff acceptance rates, and court rulings on the divisional merger strategy are the key milestones to watch

6. M&A pipeline — With a AAA balance sheet and $18B+ in annual free cash flow, J&J is a persistent large-scale acquirer. Recent acquisitions include Shockwave Medical (intravascular lithotripsy for cardiovascular calcification, ~$13B) and Abiomed (heart assist devices, ~$17B). Watch for acquisitions in oncology, neuroscience, and MedTech robotics — categories where J&J has signalled pipeline investment priority

7. Darzalex expansion into smoldering myeloma — Clinical trials are evaluating Darzalex in smoldering (pre-symptomatic) multiple myeloma. If approved, this would dramatically expand the treatable patient population — from patients already diagnosed with active myeloma to those with precursor disease. A positive trial readout would be among the most significant near-term catalysts for J&J’s pharmaceutical segment

Johnson & Johnson (JNJ) Financial Summary

Johnson & Johnson (JNJ) is a healthcare company that generated $88.8 billion in total revenue in fiscal year 2024, up 4.2% year-over-year, with $14.1 billion in net income and a 68% gross margin. The company operates across two segments — Innovative Medicine (pharmaceuticals) and MedTech (medical devices) — and is one of only a handful of companies globally to hold both a AAA credit rating and a 60+ year streak of consecutive dividend increases.

The most critical near-term dynamics are managing the Stelara biosimilar revenue decline (beginning 2025) while scaling Darzalex, Tremfya, and Carvykti; the Ottava robotic surgery platform’s commercial launch against an entrenched Intuitive Surgical; and achieving a comprehensive talc litigation settlement.

For the broader pharmaceutical landscape, see How Pfizer Makes its Money, How AbbVie Makes its Money, and How Eli Lilly Makes its Money.